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Abstract
Background: This phase I/II-trial assessed the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of
neoadjuvant radiochemotherapy (RCT) with docetaxel and oxaliplatin in patients with locally advanced
adenocarcinoma of the oesophagogastric junction.
Methods: Patients received neoadjuvant radiotherapy (50.4 Gy) together with weekly docetaxel (20 mg/m
2 at dose
level (DL) 1 and 2, 25 mg/m
2 at DL 3) and oxaliplatin (40 mg/m
2 at DL 1, 50 mg/m
2 at DL 2 and 3) over 5 weeks.
The primary endpoint was the DLT and the MTD of the RCT regimen. Secondary endpoints included overall
response rate (ORR) and progression-free survival (PFS).
Results: A total of 24 patients were included. Four patients were treated at DL 1, 13 patients at DL 2 and 7 patients
at DL 3. The MTD of the RCT was considered DL 2 with docetaxel 20 mg/m
2 and oxaliplatin 50 mg/m
2. Objective
response (CR/PR) was observed in 32% (7/22) of patients. Eighteen patients (75%) underwent surgery after RCT. The
median PFS for all patients (n= 24) was 6.5 months. The median overall survival for all patients (n =24) was
16.3 months. Patients treated at DL 2 had a median overall survival of 29.5 months.
Conclusion: Neoadjuvant RCT with docetaxel 20 mg/m
2 and oxaliplatin 50 mg/m
2 was effective and showed a
good toxicity profile. Future studies should consider the addition of targeted therapies to current neoadjuvant
therapy regimens to further improve the outcome of patients with advanced cancer of the oesophagogastric
junction.
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Carcinomas of the stomach and gastroesophageal junc-
tion are highly aggressive neoplasms and are the second
most common cause of cancer-related deaths worldwide.
During the past few decades, a shift in the localisation of
the tumours has been observed.
While the incidence of distal gastric cancer has been de-
creasing, adenocarcinomas of the proximal stomach and
the gastroesophageal junction, including Barrett’sc a r c i n -
oma, has steadily risen. Approximately 50% of patients
present with locally advanced disease at diagnosis and the
prognosis of these patients remains poor with a five-year
survival rate of less than 20% despite radical surgical R0
resection for curative intent [1].
Therefore, multimodal strategies have been introduced
including different neoadjuvant RCT or perioperative
chemotherapy to improve the outcome for these patients
[2-5]. Compared to chemotherapy alone, which may de-
crease distant relapse rates, the primary objectives of
neoadjuvant RCT are to downsize and downstage locally
advanced tumours to increase R0 resection rates and to
reduce local recurrence rates [6]. Furthermore, the exci-
sion of irradiated areas can result in lower long-term tox-
icity and early systemic therapy allows for better control
of tumour micrometastases. Consequently, four rando-
mised clinical trials investigated neoadjuvant RCT versus
surgery alone in localised oesophageal cancer, including
patients with tumours of the gastroesophageal junction
[7-10]. Whereas some studies showed a significant sur-
vival advantage for neoadjuvant RCT [7,10,11], few other
studies failed to do so [8,9]. In these trials, chemotherapy
given in parallel to the radiotherapy was based on cisplatin
with 5-fluorouracil (5-FU). However, combination regi-
mens using newer agents may improve patient outcomes.
The palliative therapy options for metastatic disease have
clearly improved with oxaliplatin and docetaxel, showing
fewer side effects than cisplatin and better clinical
responses, respectively [12,13], but have not yet proven to
be of tolerable and beneficial in the context of neoadju-
vant chemoradiation. Thus, this binational multi-centre
phase I/II trial examined a modern double regimen com-
prised of oxaliplatin and docetaxel combined with radi-
ation therapy (RT).
Methods
Study population
Patients with histologically proven adenocarcinoma of the
oesophagogastric junction (AEG II–III, according to the
Siewert classification) with stage I–III disease (T3 N0–N3
to T4 N0–N3) and at least one measurable lesion accord-
ing to RECIST criteria were eligible. Cancer of the oeso-
phagogastric junction was defined according to the
Siewert classification [14] whereas AEG type I is defined
as adenocarcinoma of the distal oesophagus, AEG type II
is defined as adenocarcinoma of the cardia and AEG type
III is defined as subcardial adenocarcinoma with infiltra-
tion of the oesophagogastric junction. Only patients with
AEG type II and type III were included into this study.
Patients were required to be between 18 and 75 years of
age with adequate organ function and a Karnofsky per-
formance status of≥70% at study entry. Patients with
distant metastases and any previous palliative, adjuvant
or neoadjuvant chemotherapy and/or radiotherapy or
previous surgery of the primary tumour were excluded.
Patients with any other tumour type (except basal skin cell
carcinoma or in situ cervical carcinoma that had been
successfully treated), symptomatic peripheral neuropathy
as determined by the National Cancer Institute common
toxicity criteria (NCI-CTC) grade≥2, or other serious
medical conditions, known hypersensitivity to platinum-
based substances or pregnant or breast-feeding patients
were also ineligible. Women of child-bearing potential
were advised on contraception. All patients gave written
informed consent before enrollment.
Study aims and design
This was a non-randomised, multi-centre phase I/II trial
conducted at six study sites in Germany and Israel
(Registered trial NCT00374985 at clinical trials.gov).
The design and conduct of the study complied with
good clinical practice in accordance with the Declaration
of Helsinki and all local requirements. Ethical approval
was obtained for all participating institutions.
Patients received radiotherapy together with simultan-
eous chemotherapy consisting of docetaxel and oxaliplatin
once weekly over 5 weeks. For treatment with docetaxel,
pre-medication with dexamethasone was given and con-
ventional supportive measures for nausea and vomiting
were employed. Antiemetic prophylaxis included a 5-HT3
antagonist in combination with dexamethasone or methyl-
prednisolone. Four to six weeks after completion of RCT,
the patients were scheduled to undergo surgery.
The primary objective of the study was to assess the
dose-limiting toxiticities (DLT) and the maximum toler-
ated dose (MTD) of the RCT based on the following
three dose levels (DL) of chemotherapy:
DL 1: Docetaxel: 20 mg/m
2 i.v. for 1 hour, oxaliplatin
40 mg/m
2 i.v. for 2 hours on days 1, 8, 15, 22 and 29.
DL 2: Docetaxel: 20 mg/m
2 i.v. for 1 hour, oxaliplatin
50 mg/m
2 i.v. for 2 hours on days 1, 8, 15, 22 and 29.
DL 3: Docetaxel: 25 mg/m
2 i.v. for 1 hour, oxaliplatin
50 mg/m
2 i.v. for 2 hours on days 1, 8, 15, 22 and 29.
The standard 3+3 design was planned for dose escal-
ation and 3 to 6 patients were enrolled in each cohort. Sec-
ondary objectives of the study comprised assessment of the
response rate, resectability, progression-free survival and
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Protocol-specified standard dose delays and/or dose reduc-
tions were implemented based on toxicities experienced
during the RCT in individual patients. Dose-limiting toxici-
ties (DLT) were defined as any non-haematological toxicity
(excluding alopecia, nausea and vomiting) of grade ≥3, or
any haematological toxicity as follows: neutrophils < 0.5 ×
10
9/l for a minimum of 7 days or temperature> 38.5°C,
thrombocytes<25 × 10
9/l which occurred during the RCT.
The maximum tolerated dose (MTD) was defined as the
h i g h e s td o s et h a tr e s u l t e di nD L Ti nf e w e rt h a n1i n3o r2
i n6p a t i e n t si nap a t i e n tc o h o r t .
Radiotherapy was difined in the protocol, was identical
at all dose levels and started on day 1 of the chemotherapy.
A single dose of 1.8 Gy was administered once a day and
five times a week for five weeks on days 1–5, 8–12, 15–19,
22–26 and 29–3 3f o rat o t a ld o s eo f4 5G y .T h es i x t hw e e k
of therapy included a boost of three extra radiotherapy
fractions at 1.8 Gy (days 36–38) up to a maximum total
dose of 50.4 Gy. Radiotherapy was administered using the
three-dimensional planning technique; megavoltage pho-
ton energy≥6 MV was used. Computerized imaging was
used to define the primary tumor mass and involved lymph
nodes (gross tumor volume, GTV). The recommended
margins around the GTV were 2 cm radially and 5 cm su-
periorly and inferiorly. Distal para-esophageal and abdom-
inal celiac lymph nodes were included in the clinical target
volume up to a total dose of 45 Gy. The boost volume
covered the GTV with a 2-cm margin to all directions.
Radiation exposure to lungs, heart, spinal cord, kidney, and
liver limited within predefined constraints (e.g. the mean
lung dose should not exceed 20 Gy).
Clinical assessments to confirm eligibility were to be
completed within seven days before starting therapy. Inves-
tigations to measure disease, such as endosonography,
laparoscopy and computed tomography (CT) of thorax
and abdomen, were required within 28 days before treat-
ment start. Vital signs, physical examination, clinical chem-
istry and haematology were assessed weekly during RCTas
well as prior to surgery.
Efficacy and safety assessment
Tumour assessments were performed at baseline (within
28 days prior to treatment start), prior to surgery after
completion of the RCT and every 3 months post surgery.
Tumour assessments were evaluated according to the
RECISTcriteria version 1.0. Safety was assessed by record-
ing adverse events (AE) during the treatment period,
which were graded according to NCI-CTC version 3.0.
Statistical analysis
Due to the study design, the sample size was dependent
on the number of patients treated per dose level and also
dependent on the number of dose levels. Dose escalation
was only to be performed if no DLT was observed in 3
patients. If one DLT was observed, then 3 more patients
were to be treated at that dose level. If a second patient
experienced DLT, then the MTD was defined Therefore,
a formal sample size calculation was not applicable for
phase I testing. All statistical analyses were performed
using the SAS software package V. 9.1.3 (SAS Institute,
Cary; NC, USA) on the Windows platform.
Time-to-event data was analysed with the Kaplan-
Meier method. Overall survival was defined as the time
from the date of the start of RCT to death of any cause.
Patients alive at their last follow-up were censored. The
distribution of overall survival was estimated using the
Kaplan-Meier method. Based on these curves, the esti-
mated one and two-year survival rates were extrapolated
together with their associated 95% confidence limits.
Progression-free survival was analysed at the same time.
Progression-free survival time was defined as the time
from the start of chemotherapy to documented progres-
sion according to RECIST criteria or death, whichever
occurred first.
Results
Patients
A total of 24 patients were enrolled at six participating
institutions. Table 1 summarises the patient characteristics
at baseline. The median age was 62.0 years (33–75 years)
and there were 21 male (88%) and 3 female (13%) patients.
All patients presented with a good Karnofsky performance
status at study entry with a median of 95%, ranging from
90 to 100%. For the majority of patients (75%), the tumour
was localised in the cardia (AEG II).
Safety and toxicity
T h r e ep a t i e n t sw e r ep l a n n e dt ob ee n r o l l e di nd o s el e v e l1 .
Instead, four patients were recruited as two patients were
enrolled at the same time. DLT occurred in one patient
(grade 3 non-haematological toxicity: fatigue, dehydration
and syncope). As this toxicity was considered to be unre-
lated to chemotherapy, the dose was escalated to the next
level. At dose level 2, one DLT (grade 4 thrombocytopenia)
was observed in the first cohort of three patients. There-
fore, the cohort was expanded and another five patients
were enrolled. As no further DLT occurred, the dose was
escalated to dose level 3. Again, three patients were en-
rolled. Of these, one patient experienced heartburn/dys-
pepsia grade 4 and one patient developed fatigue grade 3.
When expanding the cohort for another 4 patients, further
DLT were observed (Fatigue, diarrhea, infection) (Table 2).
Dose level 2 was therefore declared the MTD and an
additional five patients were recruited at this dose level.
Table 3 summarises the frequency distribution of all ad-
verse events of at least CTC grade 3. The most frequently
observed grade≥3 adverse events were nausea (25.0%),
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opathy did not occur and haematological toxicity was in-
frequent and was only observed in three patients.
In eleven patients, chemoradiation was delayed once
(Table 4). Adverse events were the reason for delay in five
patients. Chemotherapy was delayed due to administrative
reasons or due to patient / investigator decision in six
patients. A total of 20 patients received full-dose chemo-
therapy and dose reductions due to adverse events were
only required in three patients. Radiotherapy could be
administered as planned total dose of 45 Gy followed by a
boost of 3 times 1.8 Gy in 21/24 (88%) of all cases. One
patient discontinued radiotherapy due to thrombopenia
(final dose 39,6 Gy) and 2 patients discontinued due their
patients wish (final doses 41,4 and 10,8 Gy). The total me-
dian dose was 45 Gy (range 10.8–50.4). Since the causal
relationship of adverse events with treatment had been
requested by a total yes-no, specific toxicity of radiother-
apy was not recorded separately. However, no radiation-
specific skin toxicities or or post operation complications
were attributed to the part of radiation (Tables 3 and 5).
Post-operative complications were reported in four
patients and consisted of pericardial effusion, pleural
effusion, fever or infection each in one patient (Table 5).
One patient died due to pleural effusion and pneumo-
thorax 9 days after surgery.
Table 1 Patient characteristics at baseline per dose level
Characteristics
Dose level
1 2 3 Total
Number of patients 4 (100%) 13 (100%) 7 (100%) 24 (100%)
Age, years
N 4 13 6 23
Median (range) 55.5 (38–75) 65.0 (33–70) 56.0 (44–63) 62.0 (33–75)
Gender, n (%)
Female 1 (25%) 2 (15%) 3 (13%)
Male 3 (75%) 11 (85%) 7 (100%) 21 (88%)
KPS
N 3 12 7 22
Median (range) 100 (100–100) 90 (90–100) 100 (90–100) 95 (90–100)
Siewert classification
AEG II 2 (50%) 9 (69%) 7 (100%) 18 (75%)
AEG III 2 (50%) 4 (31%) 6 (25%)
T staging
3 3 (75%) 10 (77%) 6 (86%) 19 (79%)
4 1 (25%) 2 (15%) 1 (14%) 4 (17%)
X 1 (8%) 1 (4%)
N staging
0 2 (15%) 2 (8%)
1 2 (50%) 5 (38%) 4 (57%) 11 (46%)
2 2 (50%) 4 (31%) 2 (29%) 8 (33%)
X 2 (15%) 1 (14%) 3 (13%)
M staging
0 3 (75%) 12 (92%) 7 (100%) 22 (92%)
X 1 (25%) 1 (8%) 2 (8%)
UICC staging
II A 2 (15%) 2 (8%)
III 4 (100%) 8 (62%) 6 (86%) 18 (75%)
NK 3 (23%) 1 (14%) 4 (17%)
KPS, Karnofsky Performance Status.
UICC staging according to the 6th edition: NK in case of unknown T or N staging (Tx, Nx).
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Efficacy is summarised in Table 6. For 22 patients, overall
response data prior to surgery was available. Objective
response (CR/PR) according to the RECIST criteria was
observed in seven patients (32%) in total. Two partial
responses were observed at dose level 1 (two out of 3
patients), three patients achieved PR at dose level 2 (three
out of twelve patients (25%)) and two patients achieved
PR at dose level 3 (two out of seven patients (29%)).
A total of 18 patients underwent planned surgery (75%).
Reasons for not undergoing surgery were insufficient
performance status, concomitant medical conditions and
patient request. R0 resection was documented for 14
patients. No information regarding R classification was
available for four patients. Concordantly, a down-staging
could be achieved in a substantial number of patients: at
baseline, 18/24 (75%) patients presented with UICC stage
III disease, whereas prior to surgery, only 10/24 (42%)
patients had stage III disease by CT scan and/or endoso-
nography. Pathologic response information [15] was avail-
able in 13/18 resected patients: 6 patients showed pCR,
while 7 patients showed pPR. Despite intensified efforts,
no detailed informations from pathology reports were
available for the other five patients. Following surgery,
there were remarkably only 2 patients with stage III
disease according to the pathological reports.
The median progression-free survival of the intent-
to-treat-analysis for all patients (n= 24) was 6.5 months
(Table 7, Figure 1). Median progression-free survival for
patients at dose level 1 (n =4) was 2.25 months, for
patients at dose level 2 (n =13) 6.5 months, and for
patients at dose level 3 (n= 7) 13.5 months. The median
overall survival for all patients (n =24) was 16.3 months
(95% CI [7.6; 29.5]). Median overall survival for patients
at dose level 1 (n= 4) was 8.5 months (95% CI [5.6;
12.0]), for patients at dose level 2 (n =13) 29.5 months
(95% CI [4.8;x ]), and for patients at dose level 3 (n =7)
22.1 months (95% CI [16.3; 22.1]). Regarding response
rate and overall survival, it should be taken into consid-
eration that not all patients underwent surgery (n =six
patients (25%)), and in these the treatment was definitive
RCT rather than neoadjuvant therapy.
Table 2 Dose-limiting toxicities per dose level
Dose level
1 2 3 Total
Number of patients 4 (100%) 13 (100%) 7 (100%) 24 (100%)
Any DLTs?
No 3 (75%) 12 (92%) 2 (29%) 17 (71%)
Yes 1 (25%) 1 (8%) 5 (71%) 7 (29%)
If yes:
CTC-Grade III IV III IV III IV
Non-haematological toxicity grade≥3: 6 (25%)
- Dehydration, syncope 1
- Heartburn/dyspepsia 1
- Fatigue 2
- Diarrhea 1
- Infection 1
Haematological toxicity: 1 (4%)
- Thrombocytpenia 1
DLT, dose limiting toxicity.
Table 3 Frequency distribution of all drug-related
adverse events of at least grade 3
Dose level
Event 1 2 3 Total
Number of patients 4 (100%) 13 (100%) 7 (100%) 24 (100%)
Nausea 1 (25%) 2 (15%) 3 (43%) 6 (25%)
Vomiting 2 (50%) 2 (15%) 1 (14%) 5 (21%)
Dehydration 1 (14%) 1 (4%)
Diarrhoea 1 (14%) 1 (4%)
Dysphagia 1 (8%) 1 (4%)
Heartburn/dyspepsia 1 (14%) 1 (4%)
Fatigue 1 (25%) 1 (8%) 3 (43%) 5 (21%)
Pain 1 (14%) 1 (4%)
Platelets 1 (8%) 1 (14%) 2 (8%)
Leukocytes 1 (14%) 1 (4%)
Neutrophils 1 (14%) 1 (4%)
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In recent years, perioperative strategies and neoadjuvant
protocols have achieved significant advantages in terms of
overall survival in patients with advanced oesophagogastric
cancer. With the exception of one randomised trial [6], the
proportion of individual localisations remains unclear,
because all other trials enrolled patients with adenocarcin-
oma of the oesophagus, of the oesophagogastric junction
and of the stomach. Hence this trial was designed to specif-
ically address the issue of gastroesophageal tumours. In the
treatment of gastroesophageal tumours, neoadjuvant RCT
can achieve tumour shrinkage, leading to an increase of R0
resection rates, which in turn increases time to overall sur-
vival or even chance for cure. At the time this trial was
designed, little data were available that assessed oxaliplatin
and docetaxel with regards of safety and efficacy. There-
fore, the aim of our study was to investigate the safety
and tolerability of perioperative RCT with docetaxel and
oxaliplatin in patients with tumours of the oesophago-
gastric junction.
Overall, the treatment regimen using oxaliplatin and
docetaxel in combination with radiotherapy was well tol-
erated, with most frequently observed≥CTC grade 3 drug
related adverse events being nausea (25%), vomiting (21%)
and fatigue (21%). Hematological toxicities of>CTC grade
3 were observed to a lesser extent with thrombopenia in
8% of patients and leukopenia in 4% of patients.
Chemotherapy for GEJ tumours as part of combined
RCT was previously based on cisplatin and 5-fluorouracil.
Using CF as a neoadjuvant treatment (for 2 cycles prior to
surgery and for a total of 6 cycles in case of good tolerabil-
ity), neutropenia (20.2%) occurred in more than 10% of
patients in a trial by Ychou et al. [16]. In another trial,
using CF as sole treatment, neutropenia (57%), stomatitis
(27%), and lethargy (14%) were reported for a substantial
number of patients [17]. A study by Cunningham [12] has
shown that replacing cisplatin for oxaliplatin for treatment
of advanced gastric cancer can significantly lower the inci-
dence of toxic side effects. Even it is not possible to dir-
ectly compare chemotherapy alone with its combination
with radiation, docetaxel plus oxaliplatin reported less
toxicities and less proportions of deaths due to adverse
events than its triple combination with capacitabine in a
recent randomized phase II trial [18]. Despite its inferior-
ity in efficacy, such a double protocol may thus be a better
combination partner in RCT. Comparably, the RCT com-
bination of paclitaxel and carboplatin has recently been
Table 4 Administration of radiochemotherapy
Dose level
1 2 3 Total
Number of patients 4 (100%) 13 (100%) 7 (100%) 24 (100%)
Chemotherapy delay?
No 3 (75%) 5 (38%) 5 (71%) 13 (54%)
Yes 1 (25%) 8 (62%) 2 (29%) 11 (46%)
If yes, reason for delay:
Administrative reason 1 (100%) 4 (50%) 1 (50%) 6 (55%)
Adverse event 4 (50%) 1 (50%) 5 (45%)
Chemotherapy reduction?
No 3 (75%) 11 (85%) 6 (86%) 20 (83%)
Yes 1 (25%) 2 (15%) 1 (14%) 4 (17%)
If so, reason for reduction:
Administrative reason 1 (50%) 1 (25%)
Adverse event 1 (100%) 1 (50%) 1 (100%) 3 (75%)
Radiotherapy total dose (Gy)
Mean (SD) 46.8 (4.41) 44.45 (10.68) 46.54 (2.63) 45.45 (8.07)
Median (range) 47.7 (41.4–50.4) 45.0 (10.8–50.4) 45.0 (45.0–50.4) 45.0 (10.8–50.4)
Table 5 Frequency distribution of all adverse events
reported after surgery
Dose level
Event 1 2 3 Total
Number of patients 3 (100%) 11 (100%) 4 (100%) 18 (100%)
Any event 1 (33%) 2 (18%) 1 (25%) 4 (22%)
Pericardial effusion 1 (25%) 1 (6%)
Fever 1 (33%) 1 (6%)
Infection 1 (9%) 1 (6%)
Pleural effusion 1 (9%) 1 (6%)
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to either neoadjuvant radiochemotherapy followed by sur-
gery, or surgery alone. Here, even if esophageal cancers
were included mainly, gastroesophagel junctions tumors
were also addressed. Toxicities in this study were also low,
with hematologic toxicities occurring in 7% of patients
and non-hematologic toxicities in less than 5% of patients.
Overall, combinations of taxanes and/or oxaliplatin
with concurrent radiotherapy have been investigated
only in a limited number of investigations [20-22]. Spigel
Table 6 Surgical results and overall response
Dose level
1 2 3 Total
Number of patients 4 (100%) 13 (100%) 7 (100%) 24 (100%)
Surgery?
No 1 (25%) 2 (15%) 3 (43%) 6 (25%)
Yes 3 (75%) 11 (85%) 4 (57%) 18 (75%)
If so:
R0 2 (67%) 8 (73%) 4 (100%) 14 (78%)
Grading
G2 3 (27%) 1 (25%) 4 (22%)
G3 2 (67%) 4 (36%) 2 (50%) 8 (44%)
Information missing 1 (33%) 4 (36%) 1 (25%) 6 (33%)
Response prior to surgery (RECIST)
N 3 (100%) 12 (100%) 7 (100%) 22 (100%)
PR 2 (67%) 3 (25%) 2 (29%) 7 (32%)
SD 5 (42%) 2 (29%) 7 (32%)
PD 1 (33%) 2 (17%) 2 (29%) 1 (5%)
NK/ND 2 (17%) 1 (14%) 2 (9%)
Staging prior to surgery (UICC)
N 4 (100%) 12 (100%) 7 (100%) 23 (100%)
II A 4 (33%) 1 (14%) 5 (229%)
II B 1 (8%) 1 (14%) 2 (9%)
III 3 (75%) 4 (33%) 2 (29%) 9 (39%)
IV 1 (14%) 1 (4%)
NK/ND 1 (25%) 3 (25%) 2 (29%) 6 (26%)
Pathologic response [15]
N 3 (100%) 11 (100%) 4 (100%) 18 (100%)
CR 4 (36%) 2 (50%) 6 (33%)
PR 1 (33%) 4 (36%) 2 (50%) 7 (39%)
SD 1 (9%) 1 (6%)
PD 1 (33%) 1 (9%) 2 (11%)
NK/ND 1 (33%) 1 (9%) 2 (11%)
Staging after surgery (UICC)
N 3 (100%) 11 (100%) 4 (100%) 18 (100%)
0 2 (18%) 1 (25%) 3 (17%)
I 1 (9%) 1 (25%) 2 (11%)
II A 1 (33%) 2 (18%) 3 (17%)
II B 1 (33%) 2 (18%) 2 (50%) 5 (28%)
III 1 (9%) 1 (6%)
NK/ND 1 (33%) 3 (27%) 4 (22%)
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fatigue in 12% of patients treated with oxaliplatin, doc-
etaxel and capecitabine. They have also found a sig-
nificant amount of other drug related ≥ CTC grade 3
toxicities (anorexia, dehydration, esophagitis, and pul-
monary symptoms). Solomon et al. [23] also reported
f a t i g u e( 2 5 % )a n dd i a r r h e a( 3 1 % )t ob et h em o s tf r e -
quently observed events, along with nausea (6.25%).
These toxicity data are comparable with our observa-
tions and show that RCT with oxaliplatin and doce-
taxel can be safely administered with a dose of 20 mg/m
2
docetaxel and 50 mg/m
2 oxaliplatin as in DL2, but higher
doses of docetaxel lead to more haematological and non-
hematological toxicities. Comparably, doses of onother
preoperative RCT phaseI/II study corresponded to our
DL1 for docetaxel and oxaliplatin, however with a lower
radiation dose but additionally combined with capecita-
bine [22].
In our trial, the progression-free survival of 6.5 months
was somewhat lower than expected from other trials [22]
[24,25], while the 16.3 months overall survival compared
to the rates reported by others [7,8], but was significantly
lower than reported for the CROSS trial, where a median
overall survival of 49 months in the RCT arm and
26 months in the surgery alone arm was achieved [19]. It
should be noted that no final conclusions can be drawn
with respect to treatment efficacy out of our study with a
relatively low number of patients and wide confidence
intervals. Again, 25% of the patients did not undergo sur-
gery for various reasons (insufficient performance status,
concomitant medical conditions and patient request).
Even though this rate is substantially higher than the rate
observed in the CROSS trial, where only 10% of neoadju-
vant RCT treated patients could not be resected, it is com-
parable to those achieved in other trials [19,22].
Conclusion
In summary, from the data presented, we conclude
that docetaxel/oxaliplatin in combination with radi-
ation is a safe neoadjuvant strategy for treatment of
gastroesophageal junction cancers. Efficacy endpoints
should be confirmed in larger clinical trials, preferably
including newer biological agents and again preferably
focusing on specific esophagogastric sites to omit dif-
ferent possible post-operative morbidity and mortality
rates [26,27].
Table 7 Progression-free survival (PFS) and overall survival (OS)
Dose level
1 2 3 Total
Number of patients 4 (100%) 13 (100%) 7 (100%) 24 (100%)
PFS (months)
Median (95% CI) 2.25 (1.4, 8.1) 6.5 (2.5, n.a.) 13.5 (2.3, 14.4) 6.5 (2.3, 13.3)
OS (months)
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Figure 1 Kaplan Meier overall survival (A) and progression-free survival (B) in dose levels 1–3.
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